2019 update of the drug resistance mutations in HIV-1
Wensing, Annemarie M.; Calvez, Vincent; Ceccherini-Silberstein, Francesca; Charpentier, Charlotte; Günthard, Huldrych F.; Paredes, Roger; Shafer, Robert W.; Richman, Douglas D.
(2019) Topics in Antiviral Medicine, volume 27, issue 3, pp. 111 - 121
(Article)
Abstract
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last published in January 2017. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to
... read more
antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Antiretroviral, Drug resistance, HIV, Mutations, Therapy, Infectious Diseases, Pharmacology (medical), Virology, Pharmacology, Journal Article
ISSN: 2161-5861
Publisher: International Antiviral Society
Note: Funding Information: Funding/Support: This work was funded by IAS–USA. No commercial company or government funding was used to sup port the effort. Panel members are not compensated. The authors thank Jose Francisco for ad ministrative support for the work. Funding Information: Financial affiliations in the past 12 months: Dr Calvez has served as an advi sor or consultant to and has received research grants from Bristol-Myers Squibb, Johnson & Johnson, ViiV Healthcare, and Gilead Sciences, Inc, and is a founder of SkinDermic Pharma. Dr Ceccherini-Silberstein has been a consultant to ViiV Healthcare, Bristol-Myers Squibb, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc. Dr Charpentier serves as an advisor for ViiV Healthcare, Gilead Sciences, Inc, Janssen Therapeutics, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Healthcare. Dr Günthard has served as a consultant to Merck & Co, Inc, ViiV Healthcare, Sandoz, Teva Pharmaceutical Industries, and Gilead Sciences, Inc, and has received research grants from Gilead Sciences, Inc. Dr Paredes has received research grants from and has served as an advisor for ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc. Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Viriome, Inc. Dr Shafer has received research grants from Janssen Therapeutics, Vela Diagnostics, and InSilixa, Inc, and consulting fees from Abbott Diagnostics. Dr Wensing has served on advisory boards for ViiV Healthcare, Merck & Co, Inc, Janssen Therapeutics, and Gilead Sciences, Inc, and has received research or unrestricted educational grants from Janssen Therapeutics, ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc. Funding Information: This work was funded by IAS-USA. No commercial company or government funding was used to support the effort. Panel members are not compensated. Publisher Copyright: © 2019, International Antiviral Society. All rights reserved.
(Peer reviewed)